|
Malignant neoplasm of prostate
|
0.800 |
Biomarker
|
disease |
BEFREE |
The purpose of this article is to provide a review of principles of genetic testing in prostate cancer and highlight the significance of clinical genetic testing of BRCA1/2 and other genes (CHEK2, HOXB13, PALB2), including Lynch syndrome genes (MLH1, MSH2, MSH6, and PMS2) in men with metastatic prostate cancer.
|
30681994 |
2019 |
|
Malignant neoplasm of prostate
|
0.800 |
Biomarker
|
disease |
BEFREE |
A number of germline mutations in DNA damage repair genes ( BRCA1, BRCA2, CHEK2, ATM and PALB2) and in DNA mismatch repair genes ( MLH1, MSH2, MSH6 and PMS2) can drive the development of prostate cancer.
|
30730411 |
2019 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We found monoallelic truncating/functionally deleterious mutations in seven genes, including ATM and CHEK2, which have previously been associated with PrCa predisposition, and five new candidate PrCa associated genes involved in cancer predisposing recessive disorders, namely RAD51C, FANCD2, FANCI, CEP57 and RECQL4.
|
29659569 |
2018 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
No association was found between CHEK2 mutation status and early-diagnosis or PCa-specific survival time.
|
29520813 |
2018 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men.
|
27595995 |
2016 |
|
Malignant neoplasm of prostate
|
0.800 |
Biomarker
|
disease |
BEFREE |
In conclusion, we propose that CHK2 is a negative regulator of androgen sensitivity and prostate cancer growth, and that CHK2 signaling is lost during prostate cancer progression to castration resistance.
|
26573794 |
2015 |
|
Malignant neoplasm of prostate
|
0.800 |
Biomarker
|
disease |
BEFREE |
Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer: a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation.
|
26447757 |
2015 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CHEK2 is a multi-cancer susceptibility gene whose common germline mutations are known to contribute to the risk of developing breast and prostate cancer.
|
24986639 |
2014 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mutations in CHEK2 have been associated with cancers at many sites, including breast and prostate cancers, but the relationship between CHEK2 and gastric cancer has not been extensively studied.
|
23296741 |
2013 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that testing for germline CHEK2 mutations improves the ability to predict the presence of prostate cancer in screened men, however, the clinical utility of incorporating DNA variants in the screening process is marginal.
|
23722471 |
2013 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To establish the contribution of eight founder alleles in three DNA damage repair genes (BRCA1, CHEK2 and NBS1) to prostate cancer in Poland, and to measure the impact of these variants on survival among patients.
|
23149842 |
2013 |
|
Malignant neoplasm of prostate
|
0.800 |
Biomarker
|
disease |
BEFREE |
To investigate whether it plays an important role in the development of prostate cancer (PRCA) in the Ashkenazi Jewish (AJ) population, we sequenced CHEK2 in 75 AJ individuals with prostate, breast, or no cancer (n=25 each).
|
18571837 |
2008 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Intriguingly, two other CHEK2 mutations (IVS2+1G>A and I157T) and a CHEK2 large genomic deletion (del9-10) have been associated with an elevated risk for prostate cancer.
|
17661168 |
2008 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in CHEK2 have been associated with a range of cancer types but little is known about disease risks conveyed by CHEK2 mutations outside of the context of breast and prostate cancer.
|
17918154 |
2008 |
|
Malignant neoplasm of prostate
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, heat treatment induced the phosphorylation of Chk2 proteins examined and led to apoptosis in the prostate cancer cells.
|
18507002 |
2008 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Modest effects on prostate cancer risk were observed for both CHEK2 missense and truncating variants.
|
17372254 |
2007 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that the CHEK2 and TP53 mutations can substitute each other in at least 25% (21/84) of prostate cancers and that DNA damage-signaling pathway plays an important role in prostate cancer tumorigenesis.
|
16941491 |
2006 |
|
Malignant neoplasm of prostate
|
0.800 |
Biomarker
|
disease |
BEFREE |
Taken together, these results provide evidence that both germline and somatic CHEK2 mutations identified in prostate cancer may contribute to the development of prostate cancer through the reduction of CHEK2 activation in response to DNA damage and/or oncogenic stress.
|
16835864 |
2006 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A large deletion of exons 9 and 10 of CHEK2 confers an increased risk of prostate cancer in Polish men.
|
17085682 |
2006 |
|
Malignant neoplasm of prostate
|
0.800 |
Biomarker
|
disease |
BEFREE |
Germ line mutations in several genes (BRCA1, BRCA2, and CHEK2) whose products are involved in the DNA damage-signaling pathway have been implicated in prostate cancer risk.
|
17079449 |
2006 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The relatives of bilateral cases who were wild-type for CHEK2 had three times the population risk of female breast cancer (145 cases: SIR 3.48 (95% CI 2.96-4.09), twice the risk of prostate cancer (34 cases: SIR 2.41, 1.67-3.36) and a large excess of male breast cancer (five cases: SIR 15.06, 4.92-35.36).
|
16257342 |
2005 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The risk of prostate cancer is known to be elevated in carriers of germline mutations in BRCA2, and possibly also in carriers of BRCA1 and CHEK2 mutations.
|
15280931 |
2004 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Our results provide evidence that the two truncating mutations of CHEK2 confer a moderate risk of prostate cancer in Polish men and that the missense change appears to confer a modest risk.
|
15087378 |
2004 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A single founder allele of the CHEK2 gene has been associated with predisposition to breast and prostate cancer in North America and Europe.
|
15492928 |
2004 |
|
Malignant neoplasm of prostate
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Overall, our data suggest that mutations in CHEK2 may contribute to prostate cancer risk and that the DNA-damage-signaling pathway may play an important role in the development of prostate cancer.
|
12533788 |
2003 |